Cargando…

Role of CA 19.9 in the Management of Resectable Pancreatic Cancer: State of the Art and Future Perspectives

Background: Surgery still represents the gold standard of treatment for resectable pancreatic ductal adenocarcinoma (PDAC). Neoadjuvant treatments (NAT), currently proposed for borderline and locally advanced PDACs, are gaining momentum even in resectable tumors due to the recent interesting concept...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coppola, Alessandro, La Vaccara, Vincenzo, Farolfi, Tommaso, Fiore, Michele, Cammarata, Roberto, Ramella, Sara, Coppola, Roberto, Caputo, Damiano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495897/ https://www.ncbi.nlm.nih.gov/pubmed/36140192 http://dx.doi.org/10.3390/biomedicines10092091

Ejemplares similares

CA19.9 Serum Level Predicts Lymph-Nodes Status in Resectable Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis
por: Coppola, Alessandro, et al.
Publicado: (2021)

Role of Neoplastic Markers in Pancreatic Adenocarcinoma
por: Coppola, Alessandro, et al.
Publicado: (2022)

New Frontiers of Early Diagnosis of Pancreatic Fistula after Pancreaticoduodenectomy
por: Coppola, Alessandro, et al.
Publicado: (2022)

Special Issue “Hepatobiliary and Pancreatic Cancers: Novel Strategies for of Diagnosis and Treatments”
por: Coppola, Alessandro, et al.
Publicado: (2022)

Right hepatic artery anomalies in pancreatoduodenectomy—a risk for arterial resection but not for postoperative outcomes
por: La Vaccara, Vincenzo, et al.
Publicado: (2023)

Postoperative procalcitonin is a biomarker for excluding the onset of clinically relevant pancreatic fistula after pancreaticoduodenectomy
por: Coppola, Alessandro, et al.
Publicado: (2023)

Neoadjuvant Treatments for Pancreatic Ductal Adenocarcinoma: Where We Are and Where We Are Going
por: Coppola, Alessandro, et al.
Publicado: (2023)

Different Biliary Microbial Flora Influence Type of Complications after Pancreaticoduodenectomy: A Single Center Retrospective Analysis
por: Coppola, Alessandro, et al.
Publicado: (2021)

Data of postoperative complications related to fibrinogen-to-albumin ratio in pancreatic resections()
por: La Vaccara, V., et al.
Publicado: (2022)

Nanotechnology and pancreatic cancer management: State of the art and further perspectives
por: Caputo, Damiano, et al.
Publicado: (2021)

Preoperative systemic inflammatory biomarkers and postoperative day 1 drain amylase value predict grade C pancreatic fistula after pancreaticoduodenectomy
por: Caputo, Damiano, et al.
Publicado: (2020)

Phase II study of induction chemotherapy followed by chemoradiotherapy in patients with borderline resectable and unresectable locally advanced pancreatic cancer
por: Fiore, Michele, et al.
Publicado: (2017)

Detection of Pancreatic Ductal Adenocarcinoma by Ex Vivo Magnetic Levitation of Plasma Protein-Coated Nanoparticles
por: Digiacomo, Luca, et al.
Publicado: (2021)

Validations of new cut-offs for surgical drains management and use of computerized tomography scan after pancreatoduodenectomy: The DALCUT trial
por: Caputo, Damiano, et al.
Publicado: (2022)

Advances in pre-treatment evaluation of pancreatic ductal adenocarcinoma: a narrative review
por: Fiore, Michele, et al.
Publicado: (2023)

Utility of preoperative systemic inflammatory biomarkers in predicting postoperative complications after pancreaticoduodenectomy: Literature review and single center experience
por: Coppola, Alessandro, et al.
Publicado: (2021)

Inflammatory biomarkers and nanotechnology: new insights in pancreatic cancer early detection
por: Caputo, Damiano, et al.
Publicado: (2023)

A Bio-Imaging Signature as a Predictor of Clinical Outcomes in Locally Advanced Pancreatic Cancer
por: Fiore, Michele, et al.
Publicado: (2020)

Multiplexed Detection of Pancreatic Cancer by Combining a Nanoparticle-Enabled Blood Test and Plasma Levels of Acute-Phase Proteins
por: Caputo, Damiano, et al.
Publicado: (2022)

CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
por: Maggino, Laura, et al.
Publicado: (2022)

Combination Therapy with a Bispecific Antibody Targeting the hERG1/β1 Integrin Complex and Gemcitabine in Pancreatic Ductal Adenocarcinoma
por: Lottini, Tiziano, et al.
Publicado: (2023)

Factors Predicting Pathological Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer: The Experience of a Single Institution with 269 Patients (STONE-01)
por: Fiore, Michele, et al.
Publicado: (2021)

Stratifying Risk for Pancreatic Cancer by Multiplexed Blood Test
por: Digiacomo, Luca, et al.
Publicado: (2023)

The prognostic and predictive value of serum CA19.9 in pancreatic cancer
por: Humphris, J. L., et al.
Publicado: (2012)

The additive value of CA19.9 monitoring in a pancreatic cyst surveillance program
por: Levink, Iris J. M., et al.
Publicado: (2023)

Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer
por: Dong, Dong, et al.
Publicado: (2018)

Protein Corona Fingerprints of Liposomes: New Opportunities for Targeted Drug Delivery and Early Detection in Pancreatic Cancer
por: Palchetti, Sara, et al.
Publicado: (2019)

Prospective study of cetuximab and gemcitabine in combination with radiation therapy: feasibility and efficacy in locally advanced pancreatic head cancer
por: Fiore, Michele, et al.
Publicado: (2015)

Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9
por: Makawita, Shalini, et al.
Publicado: (2013)

Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer
por: Jahan, Rahat, et al.
Publicado: (2019)

Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours
por: Sefrioui, David, et al.
Publicado: (2017)

Significant increased CA199 levels in acute pancreatitis patients predicts the presence of pancreatic cancer
por: Teng, Dongling, et al.
Publicado: (2018)

Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis?
por: Woei-A-Jin, F J Sherida H, et al.
Publicado: (2016)

Synergistic Analysis of Protein Corona and Haemoglobin Levels Detects Pancreatic Cancer
por: Caputo, Damiano, et al.
Publicado: (2020)

Editorial: Improving surgical outcomes after pancreatic resection
por: Caputo, Damiano, et al.
Publicado: (2022)

Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer
por: Schultz, Nicolai A., et al.
Publicado: (2013)

A combination of circulating tumor cells and CA199 improves the diagnosis of pancreatic cancer
por: Chen, Junliang, et al.
Publicado: (2022)

Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: A Modern Context for an Ancient Disease
por: Gallo, Paolo, et al.
Publicado: (2023)

Editorial of Special Issue “Embolization Techniques: State of the Art and Future Perspectives”
por: Venturini, Massimo, et al.
Publicado: (2022)

Personalized Graphene Oxide-Protein Corona in the Human Plasma of Pancreatic Cancer Patients
por: Di Santo, Riccardo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_setkongvmedvj3rnt4atdbutbo